BioSpace News Archive

Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted eight new employees options to purchase a total of 33,200 shares of the Company’s common stock at an exercise price per share of $18.66, which was the closing price on September 25, 2023, and restricted stock units to acquire a total of 16,600 shares of the Company’s common stock.

Lucid Scientific, a life science instruments company that manufactures Resipher, announced the completion of a $7 million Series A financing led by IAG Capital Partners.

SK Biopharmaceuticals and Proteovant Therapeutics, today announced they will present data on the discovery and characterization of a selective IKZF2 molecular glue degrader with best-in-class potential, and on MOPED™, a novel platform for the discovery of molecular glues, at the 20th Annual Discovery on Target Conference being held in Boston, September 25-28, 2023.

RemeGen Co., Ltd. (“RemeGen” or “the Company”) (HKG: 9995, SHA: 688331), a fully-integrated commercial-stage biotechnology company, recently announced that Telitacicept(RC18) for injection obtained positive results in a Phase III clinical study in the treatment of patients with rheumatoid arthritis(RA) in China.

Carmot Therapeutics Inc. today announced two oral presentations to take place at the European Association for the Study of Diabetes Annual Meeting from October 2-6, 2023 in Hamburg, Germany.

Through decades of strategic research and development investment, the Medisca name has become synonymous with innovative, customer-focused technologies.

HepaTx is pleased to announce the recent issuance of a new patent by the Canadian Intellectual Property Office on August 22, 2023. The patent, titled “Methods and Compositions for Producing Hepatocyte-Like Cells,

Synfini, Inc. announced that it has acquired rights to the patented Synfini® platform from SRI International®, and that it will operate as an independent firm.

NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today announced the results of a retrospective comparative study of adolescent patients with functional abdominal pain disorders (FAPD) treated with IB-Stim™ therapy or standard of care medications, amitriptyline (tricyclic antidepressant) or cyproheptadine (antihistamine).

Gensco® Pharma, a specialty pharmaceutical company, in partnership with IntelGenx is announcing the anticipated launch of RizaFilm® for Q1-2024.